TY - JOUR T1 - Effects of CPAP and mandibular advancement devices on cardiac biomarkers in patients with obstructive sleep apnea JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.4738 VL - 56 IS - suppl 64 SP - 4738 AU - Iana Andreieva Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/4738.abstract N2 - Introduction: The connection between obstructive sleep apnea (OSA) and cardiovascular dysfunction is well recognized. However, the effect of continuous positive airway pressure (CPAP) and mandibular advancement devices (MAD) on different cardiovascular outcomes are conflicting, in particular as regards to impact on cardiac biomarkers.The aim of the study was to compare the effects of CPAP and MAD on cardiovascular biomarkers in patients with OSA.Methods: 80 patients with severe OSA and without cardio-vascular pathologies were included and randomized to either MAD (44 patients) or CPAP (36 patients) in this parallel study. Blood samples were taken at baseline and at 3 and 6 months after the starting of CPAP and MAD. Sensitive immunoradiometric assays were used to measure NTproBNP, galectin–3 and soluble ST-2.Results: Level of NTproBNP significantly decreased after 3 and 6 months of CPAP (from 197,33±6,79 ng/ml to 118,27±5,82 ng/ml and 109,7±5,26 ng/ml respectively, p˂0,001) and use of MAD (from 186,58±5,81 ng/ml to 152,17±7,14 ng/ml and 143,5±6,14 ng/ml respectively, p˂0,001). No significant difference was showed in Galectin-3 at 3 months in both groups (p=0,722, p=0,684). But galectin-3 significantly decreased at 6 months after CPAP (by 37,4%) and MAD treatment (by 20,1%). The level of sST-2 significantly decreased only in CPAP group at 6 months of treatment.Conclusions: CPAP was more effective than MAD after 3 and 6 months. There were improvements in all biomarkers (NTproBNP, galectin – 3 and sST-2) with CPAP and only in NTproBNP and galectin-3 in long-term MAD.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4738.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -